Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer - Wang, Xiao-Shan; Bai, Yi-Feng; Verma, Vivek; Yu, Rui-Lian; Tian, Wei; Ao, Rui; Deng, Ying; Zhu, Xue-Qiang; Liu, Hao; Pan, Hai-Xia; Yang, Lan; Bai, Han-Song; et al. (JNCI : Journal of the National Cancer Institute, 2023)
Keywords: Adenocarcinoma; Biopsy; Brain cancer; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - radiotherapy; Epidermal growth factor receptors; ErbB Receptors - genetics; Fractions; Gefitinib; Growth factors; Humans; Inhibitor drugs; Kinases; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - radiotherapy; Metastases; Metastasis; Mutation; Next-generation sequencing; Non-small cell lung carcinoma; Pneumonitis; Protein Kinase Inhibitors - adverse effects; Radiation therapy; Randomization; Sequences; Small cell lung carcinoma; Statistical analysis; Statistical tests; Survival; Targeted cancer therapy; Tumors; Tyrosine; Tyrosine Kinase Inhibitors